[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-denervation-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-denervation-therapy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100576284","efficacy-and-safety-of-renal-denervation-on-isolated-diastolic-hypertension-100576284",false,"NCT06783296","Efficacy and Safety of Renal Denervation on Isolated Diastolic Hypertension","Efficacy and Safety of Renal Denervation on Isolated Diastolic Hypertension: A Multicenter, Double-Blind, Randomized, Sham-Controlled Clinical Trial","Inclusion Criteria\n\n1. Age ≥18 years, with no restriction on sex or ethnicity;\n2. Diagnosis of primary hypertension, with no prior use of antihypertensive medication, and in the untreated state presenting with office systolic blood pressure (SBP) \\\u003C140 mmHg and diastolic blood pressure (DBP) ≥90 mmHg, as well as 24-hour ambulatory blood pressure monitoring (ABPM) showing SBP \\\u003C130 mmHg and DBP ≥80 mmHg;\n3. Willingness to participate and provision of written informed consent.\n\nExclusion Criteria\n\n1. DBP ≥110 mmHg;\n2. Secondary hypertension;\n3. Requirement for antihypertensive or blood pressure-lowering medications due to comorbid conditions (e.g., SGLT2 inhibitors, GLP-1 receptor agonists);\n4. Cardiac arrhythmias interfering with blood pressure measurement (e.g., atrial fibrillation);\n5. Contraindications to RDN, including renal transplantation, renal insufficiency (eGFR \\\u003C45 mL\u002Fmin\u002F1.73 m²), renal artery anatomy unsuitable for the procedure (inability to access the renal vasculature; renal artery diameter \\\u003C4 mm or length \\\u003C20 mm; hemodynamically or anatomically significant renal artery abnormalities or stenosis; prior coronary or renal artery interventions including angioplasty or stenting), and severe hepatic impairment;\n6. Contraindications to interventional procedures such as coagulopathy;\n7. Pregnancy, planning pregnancy, or breastfeeding;\n8. Life expectancy \\\u003C1 year;\n9. Participation in another clinical trial.","ALL","18 Years",{"count":19,"type":20},124,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to evaluate the efficacy and safety of renal denervation (RDN) in patients with isolated diastolic hypertension (IDH). The randomized, double-blind, sham-controlled, multicenter clinical trial will recruit 124 participants (62 in the treatment group and 62 in the sham control group) to assess changes in mean 24-hour ambulatory diastolic blood pressure over a 6-month follow-up period. The study is expected to provide evidence for the use of RDN as a treatment for IDH.",[26,27],"Hypertension","Renal Denervation Therapy","NOT_YET_RECRUITING","2026-01-28",{"date":31,"type":32},"2026-02-02","ACTUAL",{"date":34,"type":20},"2026-01-01",{"date":36,"type":20},"2028-07-31",{"name":38,"class":39},"Shanghai 10th People's Hospital","OTHER"]